Eversept Partners, LP Biocryst Pharmaceuticals Inc Call Options Transaction History
Eversept Partners, LP
- $993 Million
- Q2 2025
Call Options
1 transactions
Others Institutions Holding BCRX
# of Institutions
315Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$150 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$146 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$62.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$62 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$41.8 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.36B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...